HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rheumatology
Cohort
Lower vitreous CREG1 levels associated with reduced ranibizumab response in diabetic macular edema
Low CREG1 levels may link to poor treatment response
This retrospective cohort study of 189 patients with diabetic macular edema found that lower vitreous CREG1 levels were associated with non-…
New findings suggest that certain protein levels and blood markers might help identify which patients respond to diabetic macular edema trea…
Frontiers
Apr 30, 2026
Ophthalmology
RCT
Post hoc analysis compares brolucizumab and aflibercept for diabetic macular edema
A New Eye Injection Works Even If You've Had Treatment Before
A post hoc analysis of a randomized trial in 517 participants with diabetic macular edema compared intravitreal brolucizumab to aflibercept …
People with diabetic eye disease who have already tried other injections may still get meaningful vision improvement from brolucizumab.
Apr 14, 2026
Ophthalmology
RCT
Subretinal saline injection added to vitrectomy for diabetic macular edema with hard exudates
Does a simple salt solution injection help eyes with diabetic swelling?
A randomized trial in 56 patients with diabetic macular edema and hard exudates compared vitrectomy with subretinal balanced salt solution i…
A simple salt solution injection under the retina helped patients with diabetic eye swelling see better and reduced fluid buildup within sev…
Apr 9, 2026
Ophthalmology
FDA Approval
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea.
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
FDA
Apr 7, 2026
Rheumatology
Cohort
CA-1 levels elevated in aqueous humor of DME patients compared to controls in cross-sectional study
Study finds elevated protein levels in eye fluid of patients with diabetic macular edema
A retrospective cross-sectional study of 74 DME patients and 30 controls found carbonic anhydrase-1 (CA-1) levels in aqueous humor were mark…
Patients with diabetic macular edema have eye fluid protein levels about 10 times higher than those without the condition.
Frontiers
Apr 2, 2026